Showing 7971-7980 of 10397 results for "".
- New Technology Helps Identify Two Rare Skin Cell Subtypeshttps://practicaldermatology.com/news/20120515-new_technology_helps_identify_two_rare_skin_cell_subtypes/2459799/
- Merz CEO Focused on Advancing the Companyhttps://practicaldermatology.com/news/20120515-merz_ceo_focused_on_advancing_the_company/2459801/William “Bill” Humphries, newly appointed CEO of Merz, Inc., has been setting the record straight. For example, addressing a recent injunction that bars the marketing of Xeomin for aesthetic indications, he insists, “the impact of the injunction isn
- Ulthera Cleared in Mexicohttps://practicaldermatology.com/news/20120320-ulthera_cleared_in_mexico/2459837/Ulthera is now registered in Mexico to market and distribute its ultrasound therapy device, the Ulthera System. In Mexico, the system is now prescribed to produce stimulation in tissues to raise the temperature in a localized manner for aesthetic
- Judge Blocks Launch of Xeomin for Aesthetic Indicationshttps://practicaldermatology.com/news/20120307-judge_blocks_launch_of_xeomin_for_aesthetic_indications/2459852/The planned March 12 launch of Merz's Xeomin (incobotulinumtoxinA) for aesthetic indications will almost certainly be delayed due to a court order blocking marketing of incobotulinumtoxinA. The order comes in response to a suit by
- FDA Approves Methoxsalen USP Providerhttps://practicaldermatology.com/news/20120229-fda_approves_methoxsalen_usp_provider/2459859/FDA has approved a secondary supplier of Methoxsalen USP, prescribed under the brand name Oxsoralen-Ultra® (methoxsalen) Capsules, USP, 10mg. Valeant Dermatology, a division of Valeant Pharmaceuticals North America LLC, and marketer of the
- Hair Prosthetic Injuries Disproportionately Affect Women in US Emergency Departmentshttps://practicaldermatology.com/news/hair-prosthetic-injuries-disproportionately-affect-women-in-us-emergency-departments/2485826/A recent analysis of the National Electronic Injury Surveillance System (NEISS) looking at hair prosthetic–related injuries presenting to US emergency departments (EDs) between 2013 and 2022 suggested these injuries disproportionately affect women.
- Analysis: Biologics Linked to Lower Cardiometabolic Risk in HShttps://practicaldermatology.com/news/analysis-biologics-linked-to-lower-cardiometabolic-risk-in-hs/2485805/Biologics were associated with a lower incidence of type 2 diabetes mellitus (T2DM) and cardiovascular events vs. no biologic use in a TriNetX cohort of 291,283 patients with hidradenitis suppurativa (HS), according to a new study in the Journal of Drugs in Dermatology. Investigat
- BE RADIANT: Bimekizumab Delivers Durable Plaque PsO Gains Through 3 Yearshttps://practicaldermatology.com/news/be-radiant-bimekizumab-delivers-durable-pro-gains-through-3-years/2485749/Bimekizumab treatment was associated with rapid and sustained improvements in patient-reported outcomes (PROs) among adults with moderate to seve
- TOGETHER-PsO: Combination Therapy Links Obesity Treatment to Psoriasis Clearancehttps://practicaldermatology.com/news/together-pso-trial-links-obesity-treatment-to-enhanced-psoriasis-clearance/2485716/New data show that a combination therapy of ixekizumab (Taltz) plus tirzepatide (Zepbound) was superior to ixekizumab alone for achieving PASI 100 and ≥10% weight loss at 36 weeks in adults with moderate-to-severe plaque psoriasis. The phase 3b TOGETHER-PsO
- Commentary: Is the IMQ Mouse Model Hindering Psoriasis Research?https://practicaldermatology.com/news/commentary-is-the-imq-mouse-model-hindering-psoriasis-research/2485698/A perspective piece in the Journal of Investigative Dermatology takes a criticial look at the imiquimod (IMQ) mouse model, suggesting its unversality and commonality may be impeding translational progress in psoriasis resea